Amicus Therapeutics has demonstrated solid revenue growth driven by expanded sales of its Fabry and Pompe disease treatments, Galafold® and Pombiliti® + Opfolda®. The recent exclusive U.S. license for DMX-200, addressing focal segmental glomerulosclerosis (FSGS), adds a clinical-stage asset targeting an orphan kidney disorder with no approved U.S. therapies, enhancing its portfolio diversification. Financially, Amicus achieved a positive operating income swing and operating cash flow turnaround in 2025, supported by effective commercialization and manufacturing strategies, though net losses persist amid continued R&D investment. Going forward, regulatory milestones for DMX-200, ongoing reimbursement approvals, and merger developments with BioMarin represent key catalysts while competitive and regulatory risks remain notable.